Genomictree Inc.
228760
Rang in Aktien
#18739
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Aktienkurs
$7.00
Marktkapitalisierung
$171.81M
Veränderung (1 Tag)
6.44%
Veränderung (1 Jahr)
-47.27%
Land
KR
Handel Genomictree Inc. (228760)
Kategorie
Healthcare
Kursverlauf für Genomictree Inc. (228760)
Höchster Schlusskurs: $7.30 am 2026-10-01
Niedrigster Schlusskurs: $3.98 am 2017-04-01
Niedrigster Schlusskurs: $3.98 am 2017-04-01
Kursverlauf der Aktie von Genomictree Inc. von 2017 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | -34.69% |
| 2025 | 31.68% |
| 2024 | 6.73% |
| 2023 | 91.06% |
| 2022 | -34.74% |
| 2021 | -21.56% |
| 2020 | -30.26% |
| 2019 | -19.05% |
| 2018 | 267.23% |
| 2017 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $534.63 | 25.37% |
US
|
|
| $211.92 | 689.28% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $876.10 | 7.61% |
NL
|
